CMC Pharma Consulting BJ ApS: Financial statements 2025
CVR: 41988592
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
CMC Pharma Consulting BJ ApS (CVR 41988592) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 1,764,114 and a net result of DKK 30,653 compared with DKK 127,570 the year before. That is an increase of 75.3% compared with the year before. Equity in the 2025 report amounted to DKK 111,190. The solvency ratio was 49.6%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,764,114
- Profit/Loss
- DKK 30,653
- Equity
- DKK 111,190
- Total Assets
- DKK 224,317
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 1.8M | 31K | 111K | 1 |
| 2024 | - | 1M | 128K | 216K | 2 |
| 2023 | - | 4.9M | 112K | 208K | 1 |
| 2022 | - | 5.2M | 345K | 396K | 1 |
| 2021 | - | 3.5M | 611K | 651K | 1 |
Official annual report
How creditworthy is CMC Pharma Consulting BJ ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
CMC Pharma Consulting BJ ApS has published its annual report for 2024. Gross profit came to DKK 1,006,532, and the net result was DKK 127,570.
About CMC Pharma Consulting BJ ApS
CMC Pharma Consulting BJ ApS is a Danish company of the type Anpartsselskab based in Rungsted Kyst, founded in 2021. The company is registered under the industry Anden teknisk rådgivning. The management consists of Babak Jamali. The company is owned by Babak Jamali. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,764,114 and a net result of DKK 30,653 compared with DKK 127,570 the year before. Equity in the 2025 report amounted to DKK 111,190.